Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9629175 | 0.68 | — | — | |
| SCHEMBL9629177 | 0.68 | — | — | |
| SCHEMBL2144679 | 0.67 | — | — | |
| SCHEMBL9630603 | 0.67 | — | — | |
| SCHEMBL2746647 | 0.67 | — | — | |
| SCHEMBL21726 | 0.67 | — | — | |
| SCHEMBL4121654 | 0.65 | — | — | |
| SCHEMBL6594792 | 0.65 | — | — | |
| SCHEMBL1162503 | 0.65 | TSHR (0.31) | — | |
| SCHEMBL300921 | 0.64 | PNMT (0.32) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118076602-A | Heteroaryl-acetylenes, pharmaceutical compositions thereof and their therapeutic uses | 嘉兴优博生物技术有限公司 | 2024-05-24 | — | — | CN | claimed |
| US-20160340322-A1 | SUBSTITUTED TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-11-24 | — | — | US | claimed |
| EP-3085695-A1 | SUBSTITUTED TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | Nissan Chemical Industries, Ltd. (JP) | 2016-10-26 | — | — | EP | claimed |
| EP-2697232-B1 | 6,7-DIHYDROIMIDAZO[2,1-B][1,3]OXAZINE BACTERICIDES | OTSUKA PHARMA CO LTD (JP) | 2016-05-18 | — | — | EP | claimed |
| US-9051333-B2 | 6,7-dihydroimidazo [2,1-b] [1,3]oxazine bactericides | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-06-09 | — | — | US | claimed |
| EP-2697232-A1 | 6,7 - DIHYDROIMIDAZO [2, 1 - B][1, 3]OXAZINE BACTERICIDES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-02-19 | — | — | EP | claimed |
| US-20140031342-A1 | 6,7-DIHYDROIMIDAZO [2,1-b] [1,3]OXAZINE BACTERICIDES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-30 | — | — | US | claimed |
| WO-2012141338-A1 | 6,7 - DIHYDROIMIDAZO [2, 1 - B] [1, 3] OXAZINE BACTERICIDES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-10-18 | — | — | WO | claimed |
| US-6384028-B1 | TREATMENT OF CARDIOVASCULAR DISORDERS, ANTICOAGULANTS AND VALVE REPLACEMENT | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-07 | — | — | US | claimed |
| EP-0869944-A1 | N-ACYLPIPERIDINYLCARBONYLAMINOCARBOXYLIC ACIDS AND THEIR USE AS GLYCOPROTEIN IIB/IIa ANTAGONISTS AND FIBRINOGEN-BLOOD PLATELETS BINDING INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-14 | — | — | EP | claimed |
| WO-1996029309-A1 | N-ACYLPIPERIDINYLCARBONYLAMINOCARBOXYLIC ACIDS AND THEIR USE AS GLYCOPROTEIN IIB/IIa ANTAGONISTS AND FIBRINOGEN-BLOOD PLATELETS BINDING INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-09-26 | — | — | WO | claimed |
| CN-118076602-A | Heteroaryl-acetylenes, pharmaceutical compositions thereof and their therapeutic uses | 嘉兴优博生物技术有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-11890288-B2 | Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-02-06 | — | — | US | disclosed |
| CN-117203196-A | PDE4 degrading agents, pharmaceutical compositions and therapeutic applications | 拜欧斯瑞克斯公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20230364105-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-11-16 | — | — | US | disclosed |
| WO-2004039795-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-13 | — | — | WO | disclosed |
| WO-2003045921-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-05 | — | — | WO | disclosed |
| US-6384028-B1 | TREATMENT OF CARDIOVASCULAR DISORDERS, ANTICOAGULANTS AND VALVE REPLACEMENT | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
| EP-0869944-A1 | N-ACYLPIPERIDINYLCARBONYLAMINOCARBOXYLIC ACIDS AND THEIR USE AS GLYCOPROTEIN IIB/IIa ANTAGONISTS AND FIBRINOGEN-BLOOD PLATELETS BINDING INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-14 | — | — | EP | disclosed |
| WO-1996029309-A1 | N-ACYLPIPERIDINYLCARBONYLAMINOCARBOXYLIC ACIDS AND THEIR USE AS GLYCOPROTEIN IIB/IIa ANTAGONISTS AND FIBRINOGEN-BLOOD PLATELETS BINDING INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11890288-B2 | Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof | BRD4, BRD1, BRD2 | HTR2C 3405/4885 |
| US-20160340322-A1 | SUBSTITUTED TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1E, CACNA1I, CACNA1G | HTR2C 446/4885 |
| US-20230364105-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | BRD4, BRD1, BRD2 | HTR2C 3405/4885 |
| US-20140031342-A1 | 6,7-DIHYDROIMIDAZO [2,1-b] [1,3]OXAZINE BACTERICIDES | BRD1, OXA1L, QDPR | HTR2C 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.